Kk2430

Preclinical

Kyowa Kirin Co., Ltd.

Kk2430 is one of 6 therapeutic programs targeting Hematologic Neoplasms. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Hematologic NeoplasmsRecruiting

Hematologic NeoplasmsPreclinical

Recruiting

Competition

Competitive Landscape

8 competitors in Hematologic Neoplasms

#DrugCompanyPhaseTrials

Cellcept

Roche

Preclinical

1 2

Fludara

Sanofi

Preclinical

1 3

Cytoxan

BBaxter Healthcare Corporation

Preclinical

1 4

Busulfex

Akero Therapeutics

Preclinical

1 5

Rapamune

PPrism Pharmaceuticals

Preclinical

1 6

Kk2430

Kyowa Kirin Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Hematologic Neoplasms

NCT07629726

Clinical

Trials by Indication[1]

Hematologic Neoplasms1 trial

A Phase 1/2, Multicenter, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KK2430 in Participants With Hematologic Neoplasms

Recruiting· Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.·Preclinical·NCT07629726·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Kk2430. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Kk2430. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Kyowa Kirin Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: Kyowa Kirin Co., Ltd.

Kk2430

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Hematologic Neoplasms1 trial

References

Drug Info

Quick Facts

Related News